Diagnostic value of combined model based on clinicopathological and MRI features in BRCA-mutated ovarian cancer
10.3969/j.issn.1002-1671.2025.02.015
- VernacularTitle:基于临床病理和MRI特征联合模型对BRCA突变型卵巢癌的诊断价值
- Author:
Hao ZHANG
1
;
Xiaohong CHEN
1
;
Xinwei ZHONG
1
;
Yi CHEN
1
;
Bowen YUE
1
;
Shourang CHEN
1
;
Wenzhong HOU
1
;
Zhiqi YANG
1
;
Xiaofeng CHEN
1
Author Information
1. 汕头大学医学院梅州临床学院 梅州市人民医院放射科,广东 梅州 514031
- Publication Type:Journal Article
- Keywords:
ovarian cancer;
breast cancer susceptibility gene;
magnetic resonance imaging;
clinicopathological features;
diagnostic efficiency
- From:
Journal of Practical Radiology
2025;41(2):246-250
- CountryChina
- Language:Chinese
-
Abstract:
Objective To explore the diagnostic value of a combined model based on clinicopathological and MRI features in BRCA-mutated ovarian cancer.Methods The data of 132 patients with ovarian cancer who underwent pathology and BRCA gene tes-ting were analyzed retrospectively,including 52 cases of BRCA mutation group and 80 cases of BRCA wild group.The differences of MRI features and clinicopathological features between BRCA mutation group and BRCA wild group were compared.Binary logistic regression was used to construct a joint prediction model and analyze its diagnostic efficiency.Results There were significant differ-ences in cytokeratin 7(CK7),estrogen receptor(ER),Ki-67 and lymphovascular invasion(LVI)between the BRAC mutation group and the BRAC wild group(P<0.05).Univariate analysis showed that CK7,ER,Ki-67,LVI and the apparent diffusion coefficient(ADC)value of the cystic part of tumor were risk factors for BRCA-mutated ovarian cancer.The combined model based on CK7,ER,Ki-67,LVI,and the ADC value of the cystic part of tumor for the diagnosis of BRCA-mutated ovarian cancer had an area under the curve(AUC)of 0.765.Conclusion CK7,ER,Ki-67,LVI and the ADC value of the cystic part of tumor are risk factors for BRCA-mutated ovarian cancer.The combined model based on the above characteristics demonstrates good diagnostic efficacy for BRCA-mutated ovarian cancer.